Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2
Authors
Keywords
Metastatic kidney cancer, High-dose interleukin-2, Survival outcomes, Clinical benefit, Immunotherapy
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 65, Issue 8, Pages 941-949
Publisher
Springer Nature
Online
2016-06-09
DOI
10.1007/s00262-016-1854-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy
- (2017) Gary R. Hudes et al. Journal of the National Comprehensive Cancer Network
- Kidney Cancer, Version 3.2015
- (2015) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
- (2015) Michael KK Wong et al. Journal for ImmunoTherapy of Cancer
- Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
- (2014) Roxanne Payne et al. Journal for ImmunoTherapy of Cancer
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibiting Systemic Autophagy during Interleukin 2 Immunotherapy Promotes Long-term Tumor Regression
- (2012) X. Liang et al. CANCER RESEARCH
- Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
- (2012) Laurence Albiges et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma
- (2010) Brian I. Rini CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005)
- (2008) Arie S. Belldegrun et al. CANCER
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
- (2008) Jacob A. Klapper et al. CANCER
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search